Skip to main content
SpringerLink
Log in

Protein Kinase Inhibitors

  • Chapter
  • First Online:
Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures

Part of the book series: Cancer Growth and Progression ((CAGP,volume 13))

  • 1137 Accesses

Abstract

Over the last few decades, scientists have begun to unravel the molecular basis of cancer. This understanding has led to many new treatment targets. New compounds designed to specifically inhibit these targets offer great promise. Trastuzumab, imatinib, sorafenib and sunitinib are all examples of targeted inhibitors that have significantly advanced the treatment of certain malignancies. Since then there has been development of many new agents. In this chapter, we discuss the available small molecule signal transduction modulators and their affect on cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F (2007) Phase II study of vandetanib or placebo in small cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy. National cancer institute of canada council trials group study BR.20. J Clin Oncol 25:4278–4284

    Article  CAS  PubMed  Google Scholar 

  2. Arteaga C (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19:32S–40S

    CAS  PubMed  Google Scholar 

  3. Blay JY, L. C. (2005) Targeted cancer therapies. Bull Cancer 92:E13–E18

    Article  PubMed  Google Scholar 

  4. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355–365

    Article  CAS  PubMed  Google Scholar 

  5. Bukowski RM, K. F. (2006) Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC) [abstract]. J Clin Oncol 24(suppl):4523a. Abstract 4523

    Google Scholar 

  6. Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, Lenehan PF, Kaldjian EP, Varterasian ML, Jordan C, Charbonneau C, Hirte H (2005) Multicenter, randomized phase II trial of oral CI-1033 for previously treated ovarian cancer. J Clin Oncol 23:5597–5604

    Article  CAS  PubMed  Google Scholar 

  7. Casali PG, Garrett CR, Blackstein ME, Shah M, Verweij J, McArthur G, Judson I, Li J, Baum CM, Demetri GD (2006) Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol ASCO Annual Meeting Proc, Abstract #9513

    Google Scholar 

  8. De Groot JF, Gilbert MR, Hess KR, Hanna T, Groves M, Conrad C, Aldape K, Colman H, Puduvalli V, Yung WA (2007) Phase II study of combination carboplatin and erlotinib in patients with recurrent glioblastoma multiforme. J Clin Oncol ASCO Annual Meeting Proc, Abstract #2024

    Google Scholar 

  9. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480

    Article  CAS  PubMed  Google Scholar 

  10. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous. Blood 101:690–698

    Article  CAS  PubMed  Google Scholar 

  11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 5:561–566

    Article  Google Scholar 

  12. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14):1038–1042

    Article  CAS  PubMed  Google Scholar 

  13. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037

    Article  CAS  PubMed  Google Scholar 

  14. Dvorak H (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368–4380

    Article  CAS  PubMed  Google Scholar 

  15. Eisen T, Bukowski RM, Staehler M, Szczylik C, Oudard S, Stadler WM, Schwartz B, Simantov R, Shan M, Escudier B (2006) Randomized phase III trial of soRafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. ASCO Annual meeting Proc. J Clin Oncol, Abstract 4524

    Google Scholar 

  16. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor soRafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol, ASCO Annual Meeting Proc, Abstract 4510

    Google Scholar 

  17. Fields ALA, Rinaldi DA, Henderson CA, Germond CJ, Chu L, Brill KJ, Leopold LH, Berger MS (2005) An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colon cancer. ASCO Annual Meeting Proc, J Clin Oncol, Abstract # 3583

    Google Scholar 

  18. Geyer C, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Olivia C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  CAS  PubMed  Google Scholar 

  19. Gollob JA, Wilhelm S, Carter C, Kelley SL (2006) Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33:392–406

    Article  CAS  PubMed  Google Scholar 

  20. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation. Science 293:876–80

    Article  CAS  PubMed  Google Scholar 

  21. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A (2005) Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma. J Clin Oncol 31:7889–7896

    Article  Google Scholar 

  22. Hauschild A, A.S (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 17:2823–2830

    Article  Google Scholar 

  23. Herbst RS, G. G. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial- INTACT 2. J Clin Oncol 22:785–794

    Article  CAS  PubMed  Google Scholar 

  24. Herbst RS, P. D. (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899

    Article  CAS  PubMed  Google Scholar 

  25. Heymach J, P.-A. L.-B. (2007) Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol, ASCO Annual Meeting Proc, Abstract # 7544

    Google Scholar 

  26. Heymach JV, J. B. (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small cell lung cancer. J Clin Oncol 25:4270–4277

    Article  CAS  PubMed  Google Scholar 

  27. Hudes G, C. M. (2007) Temsirolimus, interferon alfa or both in advanced renal cell carcinoma. N Engl J Med 356:2271–2281

    Article  CAS  PubMed  Google Scholar 

  28. Jänne PA, VP J (2007) Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol 25:3936–3944

    Article  PubMed  Google Scholar 

  29. Kantarjian H, S. C. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346(9):645–652

    Article  CAS  PubMed  Google Scholar 

  30. Kantarjian H, G.F. (2006) Nilotinib in imatinib resistant CML and Philadelphia chromosome positive ALL. N Eng J Med 354:2542–2551

    Article  Google Scholar 

  31. Kantarjian HM, T. M. (2006) New insights into the pathophysiology of chronic myeloid leukemia. Ann Int Med 145:913–923

    PubMed  Google Scholar 

  32. Kantarjian H, P. R. (2009) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 115(18):4136–4147

    Article  CAS  PubMed  Google Scholar 

  33. Krause D, V.R. (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172–187

    Article  CAS  PubMed  Google Scholar 

  34. Kris MG, N. R. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16):2149–2158

    Article  CAS  PubMed  Google Scholar 

  35. Llovet J, R. S. (2007) SoRafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol, ASCO Annual Meeting Proc, Abstract LBA1

    Google Scholar 

  36. Martin GS (2001) The hinting of the Src. Nat Rev Mol Cell Biol 2:467–475

    Article  CAS  PubMed  Google Scholar 

  37. Mauro MJ, D. M. (2006) Chronic myeloid leukemia in 2006: a perspective. Haematologica 91:152

    CAS  PubMed  Google Scholar 

  38. McDermott DF, S. J. (2008) Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 study Groupa. J Clin Oncol 13:2178–2185

    Article  Google Scholar 

  39. Mestan J, W. E.-J. (2004) AMN107: in vitro profile of a new inhibitor of the tyrosine kinase activity of BCR-ABL Blood 104:546a. Abstract no. 1978

    Google Scholar 

  40. Moore MJ, G. D. (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the national cancer institute of canada clinical trials group (NCIC-CTG). ASCO Annual Meeting (p Abstract 1)

    Google Scholar 

  41. Motzer RJ, H. T. (2006) Phase III randomized trial of sunitinib malate (SU 11248) versus interferon alfa as first line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol, ASCO Annual Meeting Proc, Abstract 24

    Google Scholar 

  42. Motzer RJ, M. M. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24

    Article  CAS  PubMed  Google Scholar 

  43. Motzer RJ, R. B. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–2524

    Article  CAS  PubMed  Google Scholar 

  44. Nelson MH, D. C. (2006) Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40:261–269

    Article  CAS  PubMed  Google Scholar 

  45. Nissim H, S. N. (2004) Upstream and downstream of mTOR. Genes Dev 18:1926–1945

    Article  Google Scholar 

  46. Opperman H, L.A. (1979) Uninfected vertébrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (src). Proc Natl Acad Sci USA 76:1804–1808

    Article  Google Scholar 

  47. Perez EA, B. J. (2006) Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol, ASCO Annual Meeting Proc, Abstract # 583

    Google Scholar 

  48. Ranson M (2004) Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 90:2250–2255

    CAS  PubMed  Google Scholar 

  49. Rixe O, F SX (2009) A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol 64(6): 1139–1148

    Article  CAS  PubMed  Google Scholar 

  50. Rubin BP, S. S. (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118–8121

    CAS  PubMed  Google Scholar 

  51. Savage DG , A. K. (2002) Imatinib mesylate – a new oral targeted therapy. N Engl J Med 346(9):683–693

    Article  PubMed  Google Scholar 

  52. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211–225

    Article  CAS  PubMed  Google Scholar 

  53. Shah NP, T. C. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399–401

    Article  CAS  PubMed  Google Scholar 

  54. Shepherd FA, R. P. (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123–132

    Article  CAS  PubMed  Google Scholar 

  55. Soulieres D, S. N. (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Onc 22(1):77–85

    Article  CAS  Google Scholar 

  56. Sridhar SS, H. D. (2005) Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4:677–685

    Article  CAS  PubMed  Google Scholar 

  57. Strumberg D, R. H. (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965–972

    Article  CAS  PubMed  Google Scholar 

  58. Talpaz M, S. N. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531–2541

    Article  CAS  PubMed  Google Scholar 

  59. Thatcher N, C. A.-s.-c.-c. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet 366:1527–1537

    Article  CAS  PubMed  Google Scholar 

  60. Traxler P (2003) Tyrosine kinases as targets in cancer therapy – successes and failures. Expert Opin Ther Targets 7:215–234

    Article  CAS  PubMed  Google Scholar 

  61. Verweij J, C. P. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127–1134

    Article  CAS  PubMed  Google Scholar 

  62. Wells S, Y. Y. (2006) A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. J Clin Oncol, ASCO Annual Meeting Proc, Abstract #5533

    Google Scholar 

  63. Yu CL, M.D. (1995) Enhanced DNA binding activity of a Stat-3 related protein in cells transformed by the Src oncoprotein. Science 269:81–83

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Oncology, Department of Medicine, University of California, 1600 Divisadero Street, San Francisco, CA, 94010, USA

    Daanish Hoda & Adil Daud

Authors
  1. Daanish Hoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adil Daud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adil Daud .

Editor information

Editors and Affiliations

  1. Moores UCSD Cancer Center, 3855 Health Sciences Drive 0820, La Jolla, 92093-0820, California, USA

    Boris R. Minev

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Hoda, D., Daud, A. (2011). Protein Kinase Inhibitors. In: Minev, B. (eds) Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Cancer Growth and Progression, vol 13. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9704-0_17

Download citation

  • DOI: https://doi.org/10.1007/978-90-481-9704-0_17

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-9703-3

  • Online ISBN: 978-90-481-9704-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation